Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Treatment of Opioid Withdrawal

Research Question:
Will this medication reduce withdrawal symptoms during a planned opioid taper?

Basic Study Information

Purpose:
Eligible subjects will begin a planned, 14-day taper of their opioid medication and will be randomly assigned to receive the study drug, either LUCEMYRA or a placebo tablet. LUCEMYRA is currently approved for abrupt discontinuation of opioids. You may be eligible if you are 18 yrs or older, on oral opioid dosage of 50-240 MME daily for at least 12 wks, have chronic non-cancer pain for at least 6 mos, and have no cardiovascular abnormalities.

Location: 2180 South Clinton Avenue
Study Reference #: STUDY4187

Lead Researcher (Principal Investigator)

Lead Researcher:  John Markman, MD

Study Contact Information

Study Coordinator: Translational Pain Research
Phone: (585) 276-8489
Email: painresearch@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search